Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Edoxaban Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,372Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Edoxaban

    02 13Lixiana

    03 4Savaysa

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 676

    2019 Revenue in Millions : 516

    Growth (%) : 31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Savaysa

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Savaysa

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 28

    2019 Revenue in Millions : 25

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 707

    2019 Revenue in Millions : 745

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 743

    2020 Revenue in Millions : 703

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 802

    2020 Revenue in Millions : 672

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 781

    2021 Revenue in Millions : 743

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 849

    2021 Revenue in Millions : 802

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Lixiana

    Edoxaban Tosylate

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban Tosylate

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 926

    2022 Revenue in Millions : 849

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Lixiana

    Edoxaban

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 780

    2022 Revenue in Millions : 781

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Lixiana

    Edoxaban Tosylate

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    Simposio AFI
    Not Confirmed

    Daiichi Sankyo

    Edoxaban Tosylate

    Main Therapeutic Indication : Hematology

    Currency : USD

    2024 Revenue in Millions : 877

    2023 Revenue in Millions : 782

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF